Fast TILs to Treat Metastatic Pleural Effusions From Epithelial or Mesothelial Primary Tumors

This research study aims to evaluate the safety and effectiveness of a novel immunotherapy, Fast TIL, an Adoptive Cellular Therapeutic (ACT), to fight cancer that has spread to the pleura or pleural mesothelioma. The ACT product is created at AHN West Penn using the participant's pleural infiltrating T-cells (PIT). It is administered through a pleural catheter along with the drug Interleukin-2 (IL-2). Based on previous research it is believed that it may help fight the tumor and relieve symptoms. As a participant, their pleural fluid will be collected and the PIT cells will be isolated and ex

Trial Details

NCT ID
NCT07443020
Phase
PHASE1
Sponsor
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • locally manufactured adoptive cellular therapy (ACT) product
  • Interleukin-2 (IL-2)
Locations (sample)
  • Pittsburgh, Pennsylvania, United States|40.44062,-79.99589

Key Eligibility Criteria

  • Patients with symptomatic, biopsy-proven malignant to the pleura, or mesothelioma with pleural effusions. Patients must have received and be refrac…
  • Patients will be ≥ 18 and \< 80 years of age.
  • Female patients of childbearing potential must have a negative urine or serum pregnancy test and if sexually active must use an acceptable method o…
  • Male participants must be willing to practice birth control from the time of enrollment on this study and for 4 months after receiving the preparat…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →